2017Drug Safety - Case ReportsOpen access

Are Hypomanic/Manic Episodes “Induced by” or “Associated with” Quetiapine Initiation?

Rami Bou Khalil

Open full text 0 citations

Abstract

An increasing number of case reports are concerned with hypomanic/manic symptoms induced by some atypical antipsychotic drugs, especially quetiapine [ 1 ]. In the current volume of Drug Safety—Case Reports , the case series published by Rovera et al. [ 2 ] demonstrates that quetiapine-related hypomania is an interesting event that is worth being appropriately diagnosed and managed in patients with bipolar disorder. Quetiapine is a second-generation dibenzothiazepine antipsychotic drug approved for the treatment of schizophrenia, major depression, bipolar disorder, bipolar depression, and mania. Several randomized, double-blind, placebo-controlled studies with quetiapine in bipolar depression included treatment-induced hypomania/mania as a secondary outcome, although the incidence of treatment-induced hypomania/mania with quetiapine at a dose of 300 or 600 mg/day seems no higher than that with placebo [ 3 , 4 , 5 ].

Open-access reader

About this research paper

What this paper is about

An increasing number of case reports are concerned with hypomanic/manic symptoms induced by some atypical antipsychotic drugs, especially quetiapine [ 1 ]. In the current volume of Drug Safety—Case Reports , the case series published by Rovera et al. [ 2 ] demonstrates that quetiapine-related hypomania is an interesting event that is worth being appropriately diagnosed and managed in patients with bipolar disorder. Quetiapine is a second-generation dibenzothiazepine antipsychotic drug approved for the treatment of schizophrenia, major depression, bipolar disorder, bipolar depression, and mania. Several randomized, double-blind, placebo-controlled studies with quetiapine in bipolar depression included treatment-induced hypomania/mania as a secondary outcome, although the incidence of treatment-induced hypomania/mania with quetiapine at a dose of 300 or 600 mg/day seems no higher than that with placebo [ 3 , 4 , 5 ].

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

An increasing number of case reports are concerned with hypomanic/manic symptoms induced by some atypical antipsychotic drugs, especially quetiapine [ 1 ]. In the current volume of Drug Safety—Case Reports , the case series published by Rovera et al. [ 2 ] demonstrates that quetiapine-related hypomania is an interesting event that is worth being appropriately diagnosed and managed in patients with bipolar disorder. Quetiapine is a second-generation dibenzothiazepine antipsychotic drug approved for the treatment of schizophrenia, major depression, bipolar disorder, bipolar depression, and mania. Several randomized, double-blind, placebo-controlled studies with quetiapine in bipolar depression included treatment-induced hypomania/mania as a secondary outcome, although the incidence of treatment-induced hypomania/mania with quetiapine at a dose of 300 or 600 mg/day seems no higher than that with placebo [ 3 , 4 , 5 ].

Key concepts: Hypomania, Quetiapine, Mania, Bipolar disorder, Quetiapine Fumarate, Atypical antipsychotic, Psychiatry, Ziprasidone

Related papers

Back to paper searchBrowse research topicsOriginal source
Are Hypomanic/Manic Episodes “Induced by” or “Associated with” Quetiapine Initiation? — Research Paper | ScholarLens